The settlement removes the immediate threat of a hostile tender offer and gives activists board control, which typically signals a push for operational changes or a sale process. Watch the general meeting vote (within ~42 days) — if shareholders approve the full slate, the activist-aligned board will hold a 4-3 majority, enabling strategic shifts. The 60-day issuance moratorium ends in early December 2026; any ATM activity after that could signal capital needs.
Price Chart
Executive Summary
Activist investors L.I.A. Pure Capital and Invest-Pro have entered into a cooperation agreement with Evogene, resolving their proxy contest and withdrawing their planned special tender offer at $0.55/share. The agreement grants the activists four of seven board seats (two appointed immediately, two subject to shareholder vote) and imposes a 60-day standstill on both the tender offer and any new share issuance by the company. This represents a settlement that gives the activists significant board control without a hostile takeover battle.
Key Financial Metrics
Key Facts
- L.I.A. Pure Capital and Invest-Pro together beneficially own 3,057,488 ordinary shares, representing approximately 16.94% of Evogene's outstanding shares as of October 5, 2026.
- The activists withdraw their September 8, 2026 letter announcing intention to commence a special tender offer at not less than $0.55 per share.
- Two departing directors (Dr. Yael Margolin and Mr. Yoshinori Oikawa) resigned; two additional directors (Mr. Dan Falk and Dr. Adrian Percy) will resign contingent on shareholder approval.
- Two initial shareholder directors (Dr. Adi Zuluf-Shani and Mr. Oz Adler) appointed immediately; two additional nominees (Mr. Itay Maroz and Mr. Shahar Zadok) to stand for election at a general meeting within 42 days.
- If all shareholder proposals are approved, the board will consist of seven members: four activist nominees and three continuing directors (Mr. Nir Nimrodi, Mr. Ofer Haviv, Mr. Leon Y. Recanati).
- Continuing directors expected to serve a transition period of up to six months, after which they may be removed if they do not resign.
- 60-day standstill: activists cannot commence a special tender offer; company cannot issue new shares (except employee grants in ordinary course).
- The cooperation agreement is subject to shareholder approval at the general meeting; if not approved, only the initial appointments remain effective.
Financial Impact
Activists withdraw tender offer at $0.55/share; no financial consideration exchanged in the settlement. The 60-day share issuance moratorium removes near-term dilution risk.
Risk Factors
- Shareholder approval of the cooperation agreement is not guaranteed; failure would leave only the initial two activist directors in place and could reignite hostilities.
- The 60-day standstill on share issuance expires in early December 2026, after which the company could resume ATM offerings, potentially diluting existing holders.
- The transition period for continuing directors is only up to six months; a messy board transition could disrupt operations.
- The activists' stated goal of achieving 25% voting control via tender offer is shelved but not permanently abandoned — they retain the right to acquire more shares.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001213900-26-107207 |
| Document: 0001213900-26-107207-index-headers.html | 0001213900-26-107207 |
| Document: 0001213900-26-107207-index.html | 0001213900-26-107207 |
| Document: 0001213900-26-107207.txt | 0001213900-26-107207 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 3 | $0.3641 | awaiting T+60 | — | $0.3600 (−1.13%) |
Oct 6, 2026 21d ago | SC 13D/A | $0.4106 | awaiting T+60 | — | $0.3600 (−12.32%) |
Oct 6, 2026 21d ago | 6-K | $0.4106 | awaiting T+60 | — | $0.3600 (−12.32%) |
Sep 30, 2026 27d ago | 6-K | $0.4000 | awaiting T+60 | — | $0.3600 (+10.00%) |
Sep 30, 2026 28d ago | EFFECT | $0.4000 | awaiting T+60 | — | $0.3600 (+10.00%) |
Sep 4, 2026 7w ago | 6-K | $0.5379 | awaiting T+60 | — | $0.3600 (−33.07%) |
Aug 18, 2026 10w ago | 6-K | $0.5826 | awaiting T+60 | — | $0.3600 (−38.21%) |
Aug 14, 2026 10w ago | Press Release | $0.6008 | awaiting T+60 | — | $0.3600 (−40.08%) |
Jul 31, 2026 12w ago | 6-K | $0.5400 $0.3466 | ▼ −35.81% | ▼ −37.60% | $0.3600 (−33.33%) |
Jun 16, 2026 19w ago | 6-K | $0.5600 $0.4806 | ▼ −14.18% | ▼ −15.18% | $0.3600 (−35.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers